MET and non-small cell lung carcinoma: The National Comprehensive Cancer Network (NCCN) guidelines recommend “broad molecular profiling”, including BRAF, ERBB2 (HER2), MET, RET, NTRK, and ROS1, in addition to EGFR and ALK for metastatic non-small cell lung cancer (NSCLC) [4,5,6,7].